GlassScriptPhysician profile
Michael Fennell
NPI 1023765708
$3,484.82
in general payments reported to CMS, 2019-2025
19 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $427 · 2023: $1,237 · 2024: $778 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.85 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,161.02 | 2022-2025 | Uplizna, Tavneos, Evenity |
| Abbvie INC. | $883.57 | 2022-2025 | |
| Ucb, INC. | $273.92 | 2022-2025 | Cimzia, Bimzelx |
| Aurinia Pharma U.S., INC. | $219.15 | 2022-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $184.87 | 2025 | |
| Glaxosmithkline, LLC. | $180.32 | 2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $113.80 | 2022-2025 | |
| Lilly USA, LLC | $76.66 | 2022-2023 | Taltz, Olumiant |
| Pfizer INC. | $75.38 | 2022-2023 | |
| Sobi, INC | $61.23 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $59.73 | 2023-2024 | Strensiq |
| Csl Behring | $33.36 | 2024 | Hizentra |
| Organon LLC | $30.31 | 2025 | Hadlima |
| Janssen Biotech, INC. | $26.48 | 2023 | Simponi Aria, Remicade, Simponi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.98 | 2024 | Ofev |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $21.93 | 2022 | |
| Fresenius Kabi USA, LLC | $21.36 | 2025 | |
| Ani Pharmaceuticals, INC. | $18.45 | 2022 | |
| Bioventus LLC | $18.30 | 2025 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fennell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.